Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+metastatic breast cancer (MBC)

被引：0

作者：

Jagiello-Gruszfeld, A.

Tjulandin, Sergei S.

Dobrovolskava, N.

Manikhas, A.

Pienkowski, T.

Knott, A.

DeSilvio, M.

Oliva, C.

机构：

[1] Nzoz Onko Med, Olsztyn, Poland

[2] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia

[3] Russian Sci Ctr Roentgeno Radiol, Moscow, Russia

[4] St Petersburg City Oncol Dispensery, St Petersburg, Russia

[5] Inst Marii Sklodowskiej Curie, Centrum Onkol, Warsaw, Poland

[6] GlaxoSmithKline Res & Dev Ltd, London, England

[7] GlaxoSmithKline Res & Dev Ltd, Philadelphia, PA USA

来源：

CANCER RESEARCH | 2009年 / 69卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：246S / 246S

页数：1

共 50 条

[21] First-line treatment with lapatinib plus paclitaxel versus paclitaxel alone for patients with HER2+metastatic breast cancer (MBC): Quality-of-life (QOL) analysis using repeated measures and pattern mixture models
Sherrill, B.
Wu, Y.
Amonkar, M.
Arbushites, M.
DiLeo, A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[22] Capecitabine (X) combined with trastuzumab (H) as first-line therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC)
Xu, Ligong
Song, Santai
Zhu, Jianxin
Luo, Rongcheng
Li, Lejing
Jiao, Shunchang
Pan, Hongming
Tao, Ming
Su, Yongqian
Liu, Duanqi
ANNALS OF ONCOLOGY, 2004, 15 : 38 - 38
[23] Weekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy of patients (pts) with HER-2/NEU positive metastatic breast cancer (MBC):: final results of a multicenter randomized phase IIb trial
Gasparini, G
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
[24] Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients
Guan, Z.
Xu, B.
DeSilvio, M.
Newstat, B.
Moore, Y.
Makhson, A.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S345 - S345
[25] Preliminary clinical results of a randomized phase IIb study of weekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy of patients (pts) with HER-2/neu positive metastatic breast cancer (MBC).
Gasparini, G
Morabito, A
De Sio, L
Carillio, G
Gion, M
Zancan, M
Rocco, S
Crivellari, D
Spada, A
Veronesi, A
Filippelli, G
Silingardi, V
Cognetti, F
Papaldo, P
Amadori, D
BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S51 - S51
[26] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
Peacock, N. W.
Infante, J. R.
Yardley, D. A.
Burris, H. A., III
Greco, F. A.
Farley, C.
Webb, C.
Spigel, D. R.
Hainsworth, J. D.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[27] Outcome of patients treated with docetaxel versus paclitaxel in a non-randomized phase IV trial of first-line taxane/trastuzumab therapy in patients with HER2+metastatic breast cancer (MBC)
Reddy, JC
Barker, C
Lim, D
Klein, PM
BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S129 - S129
[28] Association of PTEN Loss and PIK3CA Mutations on Outcome in HER2+Metastatic Breast Cancer Patients Treated with First-Line Lapatinib Plus Paclitaxel or Paclitaxel Alone
Xu, B.
Guan, Z-Z
Shen, Z-Z
Tong, Z-S
Jiang, Z-F
Yang, J-I
DeSilvio, M.
Leigh, M.
Ellis, C.
CANCER RESEARCH, 2011, 71
[29] cMET expression in HER2+MBC patients with first-line lapatinib (L) treatment
Liu, Y.
Liu, L.
Shi, H.
Greger, J. G., Jr.
Jackson, K. D.
Marty-Ethgen, P.
Gilmer, T. M.
Martin, A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[30] An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.
Brezden, C. B.
Cantin, G.
Younus, J.
Panasci, L. C.
Klimo, P.
Laing, K. E.
Raymond, N.
Lam, W.
Trudeau, M. E.
Robidoux, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →